RxDoctor Payments Data

Savannah Tanner, PA

Physician Assistant · Santa Fe, NMNPI 1700291648

Payments from drug & device makers

$1,912in general payments, 2019–2025

Across 72 payments — averaging $26.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$656
  • Amgen$232
  • AstraZeneca$232
  • Medtronic$195
  • Actelion Pharmaceuticals US, Inc.$126
  • Janssen Scientific Affairs, LLC$120
  • plus $352 from 8 others

What the payments were for

  • Food & beverage$1,912100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,912 in reported general payments places this provider in the 85th percentile of 635 physician assistant providers in New Mexico.

See all physician assistant providers in New Mexico

Medicare billing

Part B allowed, 2024
$13,553
Medicare patients
158
Services billed
168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban295$328,651
EliquisApixaban150$184,771
EntrestoSacubitril/Valsartan46$67,478
Repatha SureclickEvolocumab82$63,859
FarxigaDapagliflozin Propanediol22$32,622
Metoprolol Succinate457$8,034
Atorvastatin Calcium456$7,056
Flecainide Acetate130$5,495
Lisinopril341$3,958
Losartan Potassium269$3,910
Carvedilol213$2,970
ClopidogrelClopidogrel Bisulfate169$2,834
Rosuvastatin Calcium119$2,441
Amlodipine Besylate201$2,095
Diltiazem 24hr Er (Cd)Diltiazem Hcl69$2,046

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$656$67,47846 claims
AstraZenecaFarxiga$232$32,62222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 635 physician assistant providers in New Mexico.

Other physician assistant in Santa Fe

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →